Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer

Pharmacogenetics

Volumn 7, Issue 4, 1997, Pages 295-302

  Kivisto ̈, Kari T ^a,d   Griese, Ernst Ulrich ^a   Stüven, Thomas ^a   Fritz, Peter ^b   Friedel, Godehard ^c   Kroemer, Heyo K ^a   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH GMBH   (Germany)

^c Thoraxchirurgische Abt Klin S   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CYP2D6; Cytochrome P450; Lung cancer

Indexed keywords

CYTOCHROME; CYTOCHROME P450;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG PARENCHYMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; BLOTTING, WESTERN; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE SUSCEPTIBILITY; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION;

EID: 0030741819     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199708000-00004     Document Type: Article

References (55)

1. Agiindez JA. Martinez C. Ladero JM. Ledesma MC. Ramos JM. Martin R. Rodriguez A. Jara C. Benitez J. Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994: 55. 0-14.
2. Ayesh R. Idle JR. Ritchie JC. Crothers MJ. Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984: 312. 69-170.
3. Bouchardy C. Benhamou S. Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 1996: 56. 51-255.
4. Caporuso NE. Shields PG. Landi MT. Shaw GL. Tucker MA. Hoover R. Sugimura H. Weston A. Harris CC. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect 1992: 98. 01-105.
5. Caporaso NE. DeBaun MR. Rothman N. Lung cancer and CYP12D6 (the debrisoquine polymorphism: sources of heterogeneity in the proposed association. Pharmacogenetics 1995: 5. S129-S134.
6. Cohen GM. Gibby KM. Mehta K. Roules of conJugation in normal and cancerous tissue from human lung, Naturer 1981: 291. 62-664.
7. Crespi CL., Penman BW. Gelboin HV. Gonzalez FJ. A tobacco smoke-derived nitrosamine. -methylnitrosaminol-l-pyridyl)-lbulanone. is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991: 12. 197-1201.
8. Czerwinski M. McLemore TL. Gelboin HV. Gonzalez FJ. Quantification of CYP2B7. CYP4B1, and CYPOR messenger RNNS in normal human lung and lung tumors. Cancer Res 1994: 54. 085-1091.
9. Ducharme MP. Warbasse LH. Edwards DJ. Disposition of intravenous and oral cyclosporinc after administraion with grapefruit Juice. Clin Pharmacol Ther 1995: 57. 85-491.
10. Duche JC. Joanne C. Barre J. de Cremoux H. Dalphin JC. Depierre A. Brochard P. Tillement JP. Bechtel P. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol 1991 : 31. 33-536.
11. Gerhardsson de Verdier M. Magman U. Peters RK. Steineck G. Overvik K. Meat, cooking methods and colorectal cancer: a case-referent study in Stockholm, Int J Cancer 1991: 49. 20-525.
12. Gonzalez FJ. Skoda RC. Kimura S. Unieno M. Zanger UM. Nebert DW. Gelboin HV. Mardwick JP. Meyer UA. Characterization of the common defect in humans deficient in debristiquitie metabolism. Nature 1988: 331. 42-446.
13. Gooderham NJ. Murray S. Lynch AM. Edwards RJ. Yadollahi-Farsani M. Bratt C. Rich KJ. Xhao K. Murray BP. Bhadresa S. Crosbie SJ. Boobis AR. Davies DS. Heteroc-yclic amines: evaluation of their role in diet associated human cancer. Br J Clin Pharmacol 1996: 42. 1-98.
14. Cough AC. Miles JS. Spurr NK. Moss JK. Caedigk A. Eichelbaum M. Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus. Nature 1990: 347. 73-776.
15. Iriinebach Kriese KH. Schumacher K. Competitive nested polymerase chain reaction for quantification of human MDRI gene expression. J Cancer Res Clin Oncol 1994: 120. 39-544.
16. Guengerich HP. Bioactivation and detoxication of toxic and carcinogen chemicals. Drug Metab Dispos 1993: 21-6.
17. Guengerich FP. Kim DM. livasaki M. Role of human cytochrome P-450 HK1 in the oxidation of many low molecular weight cancer suspects. Client Res Toxicol 1991: 4. 68-179.
18. Hakkola J. Pasanen M. Purkunen R. Saarikoski S. Pelkonen O. Maenpää J. Rane A. Raimio II. Expression of xenobioticmelabolixing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol 1994: 48. 9-64.
19. Hebert MF. Roberts JP. Prueksaritanont T. Benet LZ. Bioavailability of cyclosporine with concomitant rilainpin administration is markedly less than pretlicted by hepatic enzyme induction. Clin Pharmacol Theer 1992: 52. 55-457.
20. Hirvonen A. Musgafvel-Pursiaincn K. Anttila S. KarJalainen A. Vainio H. Polymorphism in CYP1A1 J and CYP2D6 genes: possible association with susceptibility to lung cancer. Environ Health Perspect 1995: 101 (Suppl. ). 09-112.
21. Hsu SM. Raine L. Fanger H. The use of anti-avidin antibody and avidin-biotin-complex in immunoperoxidase techniques, Am J Clin Pathol 1981: 75. 16-821.
22. Huang Z. Fasco MJ. Rgge HL. Keyomarsi K. Kaminski J.S. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996: 24. 99-905.
23. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. Polymorphisms for aromatic aminc metabolism in humans: relevance for human carcinogcnesis. Environ Health Perspect 1992: 98, 69-74.
24. 2+ -chelale affinity purification, and characterization of solubility and aggregation. Arch Biochem Biophys 1995: 321, 77-288.
25. Kivistö KT, Fritz P, Linder A, Friedel G, Beaune P, Kroemer HK. Immunohistochemical localization of cylochrome P450 BA in human pulmonary carcinomas and normal bronchial tissue. Histochemistry 1995a: 103, 25-29.
26. Kivistö KT, Linder A, Friedel G. Beaune P, Belloc C, Kroemer HK. Fritz P. Immunohistochemical localization of cytochrome P450 2E1 in human pulmonary carcinomas and normal bronchial tissue. Virchows Archiv 1995b: 426, 243-247.
27. Kivistö KT, Giriese EU, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P, Kroemer HK. Expression of cytochrome P45O BA enzymes in human lung: a combined RT-PCR and imniunohislochcmical analysis of normal tissue and lung tumours, NaumyaSchmiedeberg's Arch Pharmacol 1996: 353, 207-212.
28. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994: 26, 144-160.
29. Kroemer HK, Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995: 56, 2285-2298.
30. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase. debrisoquine 4-hydroxylase. and dextrometborphan O-demethylase in microsomes and purified cytochronie P-450 isozymes of human liver. Anal Biochem 1987: 162, 24-52.
31. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle IR. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk. Pharmacogentics 1994: 4, 107-108.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951: 193, 265-275.
33. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ. Hubbard WC. Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990: 82, 1333-1339.
34. Meier PJ, Müller HK, Dick B, Meyer UA. Hepatic monooxygenase activities in subJects with a genetic defect in drug oxidation. Gastroenterology 1983: 85, 682-692.
35. Murphy LD, Herzog CE, Rudick JB, FoJo AT, Bates SE. Use of the polymerase chain reaction in the quanfitation of mdr-1 gene expression. Biochemistry 1990: 29, 10351-10356.
36. Olkkola KT, Aranko K, Luurila H, Killer A, Saarnivaara L, Himberg JJ, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1995: 53, 298-505.
37. Olkkola KT, Backman JT, Neuvonen PJ, Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994: 55, 481-485.
38. Penman BW Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, Crespi CL. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 1993: 3, 28-39.
39. Rannug A, Alexandrie AK, Persson I, Ingelman-Sundberg M. Genetic polymorphism of cylochromes P450 1AI. D6 and 2E1. Regulation and toxicological significance. J Occup Med 1995: 37. 5-56.
40. Raunio H. Pelkonen O. Cancer genetics: genetic factors in the activation and inactivation of chemical carcinogens. In: loannidcs C. ed. Drugs, diet and disease. Volume 1: Mechanistic approaches to cancer. New York: Ellis Horwood. Ltd. 995: 229-258.
41. Raunio H. Pasanen M. Mäenpää Hakkola J. Pelkonen J. Expression of exytrahepalic cytochrome P450 in humans. In: Pacific GM. fracchia GN. eds. Advances in drug metabolism in man. Luxembourg: European Commission. Office for Official Publications of the European Communities. 995: 234-287.
42. Roots I. Drakoulis N. Ploch M. Heinemeyer Ci. Loddenkcpcr R. Minks T, Nitz M. Otte F. Koch M. Debrisoquine hydroxylation phenotypc. acetylation phenotype. and ABO blood groups as genetic host factors of lung cancer risk. Klin Wocheschr 1988: 66 (Suppl. 1) 87-97.
43. Roots I. Brockmoller J. Drakoulis N. Loddenkemper R. Mutant genes of cytochrome P450IID6. glutathione .S-transferase class Mu. and arylamine N-acetyltransferase in lung cancer patients. Clin Investig 1992:70. 07-319.
44. Shaw GL. Falk RT. Deslauriers J. Fame JN. Nesbitt JC. Pass HI. Issaq HJ. Hoover RN. Tucker MA. Debrisoquine metabolism and lung cancer risk. Cancer Epideminol Biomakers Prev 1995:4. 1-48.
45. Speirs CJ. Murray S. Davies DS. Biola-MabadeJc AF. Boobis AR. Debrisoquine oxidation phenotype and susceplibilily to lung cancer. Br J Clin I'hurnuuvl 1990:29. 01-109.
46. Stücker I. Cosine J. Laurent P. Cenee S. Beaune P. Bignon J. Depierre A. Milleron IJ. Hemon D. CYP2D6 genotype and lung cancer risk according to histologie type and tobacco exposure. Carcinogenesis 1995: 16. 759-2764.
47. Stüiven T. Criesc EU. Kroemer HK. Eichclbaum M. Zanger UM. Rapid detection of CYP2D6 null alleles by long distance- and mulliplex-polymerase chain reaction. Pharmacogenetics 1996: 6. 17-421.
48. Tefre T. Daly AK. Armstrong M. U-alhart JB. Idle JR. Brogger A. Borresen AL. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994: 4. 7-57.
49. Tomatis L ed. Cancer: causes. causes and control. Lyon: IARC Scientific Publications. 990.
50. de Waziers I. Cugnenc PH. Yang CS. IXTOUX JP. Beaune PH. Cylochrome P450 isoenzymes. epoxide hydrolase and glutathione transferases in rat and human hepatic and exlrahepatic tissues. J Pharmacol Exp Ther 1990: 253. 87-394.
51. Wheeler CVV. VVrighton SA. Cuentliner TM. Detection of human lung cylochromes P45O that are immunochcniically related to cylochromc P45O11KI and cytochrome P450IIIA. Kiochein Pharmacol 1992:44. 85-186.
52. Wolf CR. Smith CA. Cough AC. Moss JK. Vallis KA. Howard C. Carey FJ. Mills K. McNee W. Carmichael. Spurr NK. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992: 13. 035-1058.
53. Wolf CR. Smith CA. Bishop T. Forman D. Cough AC. Spurr NK. CYP2D6 genotyping and the association with lung cancer susceptibility. PhriimacifiicN 1995: 4. 04-106.
54. Xanger UM. Hauri HP. Loeper . Homherg JC. Meyer l'A. Antibodies against human cylochrome P-45(klbl in autoimmune hepatitis type II. proc Natl Acad Sci USA 1988a: 85. 256-8260.
55. Xanger UM. Vilbois F. Hardwick JP. Meyer DA. Absence of hepatic cylochrome P450buf I causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988b: 27. 447-5454.